Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate Injection

BEDFORD, Ohio, Feb. 25 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., today announced the launch of Sumatriptan Succinate Injection. This product is AP rated and is equivalent to Imitrex(R) by GlaxoSmithKline. Sumatriptan is a vascular headache suppressant indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster headache episodes. Sumatriptan Succinate Injection is not for use in the management of hemiplegic or basilar migraine.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO)

Bedford Laboratories will supply Sumatriptan Succinate Injection as a sterile aqueous solution in a 6mg (Base) / 0.5mL single-dose vial packaged in cartons containing 10 vials.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169 or at www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.

Imitrex is a registered trademark of GlaxoSmithKline